FDA Approves Viral Therapy Plus Nivolumab - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Approves Viral Therapy Plus Nivolumab

Accelerated approval is based on objective response rate and duration of response in advanced melanoma, with postapproval trials required to confirm clinical benefit.

  • By

  • Kathryn Wighton

  • August 7, 2026

  • 2 min

Share

Original Source(s)

FDA Approves Viral Therapy Plus Nivolumab

  • by Kathryn Wighton

  • August 7, 2026

Related Content

Universal Risk Stratification in Stage I–III Cutaneous Melanoma Using 31-gene Expression Profiling: A Single-Center Study

Vaccines as treatment for melanoma: an update review

Consolidative use of radiotherapy to block oligoprogression in patients with metastatic melanoma on Systemic Therapy (CURB-Melanoma) - a single arm, phase 2 clinical trial